[{"orgOrder":0,"company":"SpectronRx","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2024","type":"Partnership","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SpectronRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SpectronRx \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"SpectronRx \/ ARTBIO"}]

Find Clinical Drug Pipeline Developments & Deals by SpectronRx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : The partnership aims to produce a novel prostate cancer therapy known as AB001 (212Pb-NG001), a promising therapy for prostate cancer, by utilizing SpectronRx's expertise and facilities.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Undisclosed

                          September 01, 2024

                          Lead Product(s) : 212-Pb NG001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : ARTBIO

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : 111-In DOTA-h11B6

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Sponsor : Invicro | Johnson & Johnson Innovative Medicine | Tomopath Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Inapplicable

                          October 04, 2019

                          Lead Product(s) : 111-In DOTA-h11B6

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Invicro | Johnson & Johnson Innovative Medicine | Tomopath Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank